Focus: LifeMine Therapeutics is a Cambridge-based biotech founded in 2024 that develops therapeutics derived from fungi, representing an emerging platform approach to drug discovery. The company is early-stage and privately held, currently in Series C or later funding with no marketed products.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
Stable — net +2 jobs in 30d
2 added, 0 removed. Backfill posture.
LifeMine represents a high-risk, high-reward early-stage opportunity suitable only for career scientists and operators comfortable building infrastructure at an unproven platform company with minimal near-term visibility.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for LifeMine Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from LifeMine Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles